Search results
Results from the WOW.Com Content Network
But with earlier diagnoses and advances in treatment, HIV, the virus that causes AIDS, has become far more manageable. Death rates among diagnosed individuals have dropped, even as recently as the ...
Using WHO statistics, in 2012 the number of people living with HIV was growing at a faster rate (1.98%) than worldwide human population growth (1.1% annual), [2] and the cumulative number of people with HIV is growing at roughly three times faster (3.22%). The costs of treatment is significantly increasing burden on healthcare systems when ...
In the case of HIV exposure, post-exposure prophylaxis (PEP) is a course of antiretroviral drugs which reduces the risk of seroconversion after events with high risk of exposure to HIV (e.g., unprotected anal or vaginal sex, needlestick injuries, or sharing needles). [22]
Hemophilia A causes a deficiency in Factor VIII, a protein required for blood clotting. Factor VIII injections are a common treatment to prevent or stop bleeding in people with hemophilia A. [ 1 ] Contamination of these and other products caused large numbers of hemophiliacs to become infected with HIV and hepatitis C .
In Thailand, a one-month supply of efavirenz + Truvada, as of June 2012, cost 2,900 baht (US$90), and there is a social program for patients who cannot afford the medication. As of 2018 [update] Thailand will produce efavirenz domestically.
The human immunodeficiency virus (HIV) [8] [9] [10] is a retrovirus [11] that attacks the immune system.It is a preventable disease. [5] There is no vaccine or cure for HIV. It can be managed with treatment and become a manageable chronic health condition. [5]
In the US, etravirine is indicated for the treatment of HIV-1 infection in treatment-experienced patients aged two years of age and older. [1]In the EU, etravirine, in combination with a boosted protease inhibitor and other antiretrovirals, is indicated for the treatment of human-immunodeficiency-virus-type-1 (HIV-1) infection in antiretroviral-treatment-experienced people aged six years of ...
Zalcitabine was the third antiretroviral to be approved by the Food and Drug Administration (FDA) for the treatment of HIV/AIDS. It is used as part of a combination regimen . Zalcitabine appears less potent than some other nucleoside RTIs, has an inconvenient three-times daily frequency and is associated with serious adverse events.